Rosemary DeLuccia1, May Cheung1, Rohit Ramadoss1, Abeer Aljahdali1, Deeptha Sukumar2. 1. Nutrition Sciences Department, Drexel University, Three Parkway Building Room 392, 1601 Cherry Street, Philadelphia, PA, 19102, USA. 2. Nutrition Sciences Department, Drexel University, Three Parkway Building Room 392, 1601 Cherry Street, Philadelphia, PA, 19102, USA. deeptha.sukumar@drexel.edu.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to discuss the current knowledge about major bone regulating hormones vitamin D, parathyroid hormone (PTH), estrogen and bone metabolism markers osteocalcin (OC), bone-specific alkaline phosphatase (BAP), N-terminal propeptide of type 1 collagen (P1NP), and c-terminal type 1 collagen (CTX) and their mechanistic effects on cardiometabolic health. RECENT FINDINGS: Bone regulating hormones, nutrients, and turnover markers influence different aspects of cardiometabolic health including body composition, cardiovascular function, and glycemic control. While most observational research supports a relationship between bone as an endocrine organ and cardiometabolic outcomes, there are limited human clinical trials to strengthen a causal link between the two. While the associations between bone and cardiometabolic health are beginning to be understood based on findings from large observations studies, further exploration of bone's causal influence on health outcomes in humans and the underlying mechanisms of effect are necessary.
PURPOSE OF REVIEW: The purpose of this review is to discuss the current knowledge about major bone regulating hormones vitamin D, parathyroid hormone (PTH), estrogen and bone metabolism markers osteocalcin (OC), bone-specific alkaline phosphatase (BAP), N-terminal propeptide of type 1 collagen (P1NP), and c-terminal type 1 collagen (CTX) and their mechanistic effects on cardiometabolic health. RECENT FINDINGS: Bone regulating hormones, nutrients, and turnover markers influence different aspects of cardiometabolic health including body composition, cardiovascular function, and glycemic control. While most observational research supports a relationship between bone as an endocrine organ and cardiometabolic outcomes, there are limited human clinical trials to strengthen a causal link between the two. While the associations between bone and cardiometabolic health are beginning to be understood based on findings from large observations studies, further exploration of bone's causal influence on health outcomes in humans and the underlying mechanisms of effect are necessary.
Entities:
Keywords:
Body composition; Bone; Bone turnover; Cardiometabolic health; Cardiovascular disease; Glycemic control
Authors: H N Rosen; A C Moses; J Garber; I D Iloputaife; D S Ross; S L Lee; S L Greenspan Journal: Calcif Tissue Int Date: 2000-02 Impact factor: 4.333
Authors: Georg Goliasch; Hermann Blessberger; Danyel Azar; Georg Heinze; Johann Wojta; Christian Bieglmayer; Oswald Wagner; Martin Schillinger; Kurt Huber; Gerald Maurer; Martin Haas; Franz Wiesbauer Journal: Bone Date: 2010-11-13 Impact factor: 4.398
Authors: Carmela Maniero; Ambrogio Fassina; Teresa M Seccia; Antonio Toniato; Maurizio Iacobone; Mario Plebani; Raffaele De Caro; Lorenzo A Calò; Achille C Pessina; Gian P Rossi Journal: J Hypertens Date: 2012-02 Impact factor: 4.844
Authors: Georges Saab; Adam Whaley-Connell; Samy I McFarlane; Suying Li; Shu-Cheng Chen; James R Sowers; Peter A McCullough; George L Bakris Journal: Metabolism Date: 2009-10-02 Impact factor: 8.694
Authors: N D Quinton; R F Smith; P E Clayton; M S Gill; S Shalet; S K Justice; S A Simon; S Walters; M C Postel-Vinay; A I Blakemore; R J Ross Journal: J Clin Endocrinol Metab Date: 1999-07 Impact factor: 5.958
Authors: Karynne Grutter Lopes; Maria das Graças Coelho de Souza; Michelle da Costa Tavares Bezerra; Lucas Miranda Bessa; Paulo Farinatti; Eliete Bouskela; Miguel Madeira; Luiz Guilherme Kraemer-Aguiar Journal: Trials Date: 2022-09-02 Impact factor: 2.728